Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 41–50 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 41
- Medicine slug
- alemtuzumab
- Compared field
- volumeOfDistribution
- Comparison state
- not_comparable
- Reason codes
- DENOMINATOR_MISMATCH
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
0.18 L/kg
- Numeric value
- 0.18
- Unit
- L/kg
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Alemtuzumab label
Version not recorded · Effective date not recorded
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
14.1 L
- Numeric value
- 14.1
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6236b0bc-82e9-4447-9a78-f57d94770269 (opens source in a new tab)
Alemtuzumab label
Version not recorded · Effective date not recorded
Distribution LEMTRADA is largely confined to the blood and interstitial space with a central volume of distribution of 14.1 L.
Projected row 42
- Medicine slug
- alendronate
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 22
- Source count
- 22
- Agreement rate
- 1
- Recorded readings
0.64%
- Numeric value
- 0.64
- Unit
- %
- Source records
- 22
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 22 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a0f73a-d8cd-4197-b431-40707a2150b9 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c23fb7fe-c6b9-4f77-bde7-992222b589d3 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4323d3aa-cbb0-41e2-aba7-7a94a0516993 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2baf8516-4148-9007-e063-6394a90a8094 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09765234-01bc-40f7-b9bb-c167056f3909 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d52cf007-5775-4dea-9f43-b1907b6ffe81 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54d6543d-4239-58b1-e054-00144ff88e88 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe1dd324-eb02-4a73-97f5-9b77a7df10a7 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b63421af-ec03-1de7-e053-2a95a90abec6 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a24fd39c-34a7-4de2-9439-781e612189ca (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81589178-10c9-4806-91eb-54e638d35b8d (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14e931fd-2c5f-4d90-b7db-5980706f4a56 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:815a87c4-e489-4eb9-9a2e-fb7a16642f01 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c910bb05-279b-4ffa-a867-46f4a0853ed5 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e3ba94-d882-4b5c-87cb-af1eb0997efc (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdd2496-d253-419b-85a6-8c615f7545f1 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4358ba7-1bf8-4b0a-9407-5ac279d04555 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c4d13fb-490c-4ea9-9b04-003c8d8e9f0c (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb65442-6b3c-485c-9c5d-9cf40df4451e (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2fac28d-ad91-4cdc-a003-9fdeac073f76 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:873442b0-1932-4fa6-ba25-b4d3505f4128 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7e470d6-508e-466e-a78d-060bbbc9745c (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast.
Projected row 43
- Medicine slug
- alendronate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 22
- Source count
- 22
- Agreement rate
- 1
- Recorded readings
78%
- Numeric value
- 78
- Unit
- %
- Source records
- 22
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 22 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a0f73a-d8cd-4197-b431-40707a2150b9 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c23fb7fe-c6b9-4f77-bde7-992222b589d3 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4323d3aa-cbb0-41e2-aba7-7a94a0516993 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2baf8516-4148-9007-e063-6394a90a8094 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09765234-01bc-40f7-b9bb-c167056f3909 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d52cf007-5775-4dea-9f43-b1907b6ffe81 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54d6543d-4239-58b1-e054-00144ff88e88 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe1dd324-eb02-4a73-97f5-9b77a7df10a7 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b63421af-ec03-1de7-e053-2a95a90abec6 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a24fd39c-34a7-4de2-9439-781e612189ca (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81589178-10c9-4806-91eb-54e638d35b8d (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14e931fd-2c5f-4d90-b7db-5980706f4a56 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:815a87c4-e489-4eb9-9a2e-fb7a16642f01 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c910bb05-279b-4ffa-a867-46f4a0853ed5 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e3ba94-d882-4b5c-87cb-af1eb0997efc (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdd2496-d253-419b-85a6-8c615f7545f1 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4358ba7-1bf8-4b0a-9407-5ac279d04555 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c4d13fb-490c-4ea9-9b04-003c8d8e9f0c (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb65442-6b3c-485c-9c5d-9cf40df4451e (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2fac28d-ad91-4cdc-a003-9fdeac073f76 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:873442b0-1932-4fa6-ba25-b4d3505f4128 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7e470d6-508e-466e-a78d-060bbbc9745c (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
Protein binding in human plasma is approximately 78%.
Projected row 44
- Medicine slug
- alendronate
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 22
- Source count
- 22
- Agreement rate
- 1
- Recorded readings
28 L
- Numeric value
- 28
- Unit
- L
- Source records
- 22
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 22 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a0f73a-d8cd-4197-b431-40707a2150b9 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c23fb7fe-c6b9-4f77-bde7-992222b589d3 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4323d3aa-cbb0-41e2-aba7-7a94a0516993 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2baf8516-4148-9007-e063-6394a90a8094 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09765234-01bc-40f7-b9bb-c167056f3909 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d52cf007-5775-4dea-9f43-b1907b6ffe81 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54d6543d-4239-58b1-e054-00144ff88e88 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe1dd324-eb02-4a73-97f5-9b77a7df10a7 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b63421af-ec03-1de7-e053-2a95a90abec6 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a24fd39c-34a7-4de2-9439-781e612189ca (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81589178-10c9-4806-91eb-54e638d35b8d (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14e931fd-2c5f-4d90-b7db-5980706f4a56 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:815a87c4-e489-4eb9-9a2e-fb7a16642f01 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c910bb05-279b-4ffa-a867-46f4a0853ed5 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83e3ba94-d882-4b5c-87cb-af1eb0997efc (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdd2496-d253-419b-85a6-8c615f7545f1 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4358ba7-1bf8-4b0a-9407-5ac279d04555 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c4d13fb-490c-4ea9-9b04-003c8d8e9f0c (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb65442-6b3c-485c-9c5d-9cf40df4451e (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2fac28d-ad91-4cdc-a003-9fdeac073f76 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:873442b0-1932-4fa6-ba25-b4d3505f4128 (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7e470d6-508e-466e-a78d-060bbbc9745c (opens source in a new tab)
Alendronate label
Version not recorded · Effective date not recorded
The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans .
Projected row 45
- Medicine slug
- alfuzosin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8811cb59-6826-41d5-ab68-567338a4b883 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d163369b-e44b-4591-b166-7ddd0c1c13c0 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:644295a9-75cb-4326-a71f-b0f4e0c4cf75 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc028d5-309f-4ce3-a2d7-5804ab57677d (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride 10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37e89394-af6e-4700-bfa8-2effba1a286b (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98fa10c2-7c12-44aa-9112-e2fd6fa71d06 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f075a897-7bef-4799-b7e2-7e051c461443 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride 10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2af616e-673a-4fdd-ace8-db2d0f154604 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f42c98-4118-5f70-e053-2a95a90add02 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c01d4d6b-e030-4b8f-aaa9-4df0f3f8fbda (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a541efa-9eed-4a27-b602-7999fc6f59aa (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a530bd-6a86-251d-e053-2995a90adac4 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fc7f119-f36b-44cf-945d-940160f3afe3 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of UROXATRAL 10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffbd22eb-9df5-e0ad-e053-6294a90a7d4e (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release tablets 10 mg, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26fcc267-c8d7-e059-1bcf-830dded43690 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride extended-release 10 mg tablets, the apparent elimination half-life is 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790fe381-4a83-402e-b6c0-2ecde9cac7a7 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Following oral administration of alfuzosin hydrochloride 10 mg tablets, the apparent elimination half-life is 10 hours.
Projected row 46
- Medicine slug
- alfuzosin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
82%
- Numeric value
- 82
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43675e9d-a361-4109-9ae1-54d80580fbbd (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8811cb59-6826-41d5-ab68-567338a4b883 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d163369b-e44b-4591-b166-7ddd0c1c13c0 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:644295a9-75cb-4326-a71f-b0f4e0c4cf75 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc028d5-309f-4ce3-a2d7-5804ab57677d (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37e89394-af6e-4700-bfa8-2effba1a286b (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98fa10c2-7c12-44aa-9112-e2fd6fa71d06 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 ng/mL to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f075a897-7bef-4799-b7e2-7e051c461443 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2af616e-673a-4fdd-ace8-db2d0f154604 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 ng/mL to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f42c98-4118-5f70-e053-2a95a90add02 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 ng/mL to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c01d4d6b-e030-4b8f-aaa9-4df0f3f8fbda (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a541efa-9eed-4a27-b602-7999fc6f59aa (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 ng/mL to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a530bd-6a86-251d-e053-2995a90adac4 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fc7f119-f36b-44cf-945d-940160f3afe3 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffbd22eb-9df5-e0ad-e053-6294a90a7d4e (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26fcc267-c8d7-e059-1bcf-830dded43690 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790fe381-4a83-402e-b6c0-2ecde9cac7a7 (opens source in a new tab)
Alfuzosin label
Version not recorded · Effective date not recorded
Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).
Projected row 47
- Medicine slug
- alirocumab
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
85%
- Numeric value
- 85
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)
Alirocumab label
Version not recorded · Effective date not recorded
The absolute bioavailability of alirocumab after subcutaneous administration was about 85% as determined by population pharmacokinetics analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bcfbac2-e8ac-4569-8edc-bcde3b1fd172 (opens source in a new tab)
Alirocumab label
Version not recorded · Effective date not recorded
The absolute bioavailability of alirocumab after subcutaneous administration was about 85% as determined by population pharmacokinetics analysis.
Projected row 48
- Medicine slug
- alirocumab
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
17 to 20 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)
Alirocumab label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab at subcutaneous doses of 75 mg every 2 weeks or 150 mg every 2 weeks.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bcfbac2-e8ac-4569-8edc-bcde3b1fd172 (opens source in a new tab)
Alirocumab label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab at subcutaneous doses of 75 mg every 2 weeks or 150 mg every 2 weeks.
Projected row 49
- Medicine slug
- alirocumab
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.04 to 0.05 L/kg
- Numeric value
- 0.04
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 (opens source in a new tab)
Alirocumab label
Version not recorded · Effective date not recorded
Distribution Following intravenous administration, the volume of distribution was about 0.04 to 0.05 L/kg indicating that alirocumab is distributed primarily in the circulatory system.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bcfbac2-e8ac-4569-8edc-bcde3b1fd172 (opens source in a new tab)
Alirocumab label
Version not recorded · Effective date not recorded
Distribution Following intravenous administration, the volume of distribution was about 0.04 to 0.05 L/kg indicating that alirocumab is distributed primarily in the circulatory system.
Projected row 50
- Medicine slug
- allopurinol
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 133
- Source count
- 129
- Agreement rate
- 0.821705
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 106
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 106 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad6950d4-2cdd-44ac-9b8a-120716460e70 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f9ad8db-ae68-4a0c-b858-1e727bc98130 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:426262e6-8219-c825-e063-6294a90a21a9 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c7eafa6-5411-470c-8a45-cfbc85d3e335 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:815af471-5985-4819-936d-1f5f3d871ef8 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55280a8a-cf23-405b-b698-95a4d8e3c699 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbac3b4f-dc23-4359-ac3f-2b3fdde41af2 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f626471-153c-4740-8019-9089ea741684 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11f1fc6e-b274-4132-9edd-522a819a479b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84cd8df-79d8-449f-ace2-5a4de1cdaf51 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71accbc4-8bd7-4d22-ae53-c7b044a15ffa (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74dba96f-d388-40fe-8bca-53086d28c954 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d6ce57f-a9df-319e-e063-6394a90ac93f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdbf5ad4-86f2-4e9c-a51a-fb0c7220c480 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc7973c8-d846-4eca-ab0d-d30228035ba2 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e11e94b9-d897-48ce-9a80-aa6b8b5fde02 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76ed9122-b845-423b-a6d5-a47b31743317 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ced59048-c147-4702-af32-2f9b517ed87a (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f50e91e-66a7-4fd4-888a-9f1986aa661c (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15d758f9-2ec5-ecf5-e063-6394a90a7a2c (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3845c310-099b-8e11-e063-6394a90abd2f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df745f5f-7f05-205d-e053-2995a90a05a4 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe06da1b-c493-e238-e053-6294a90a9195 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of Allopurinol Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da814597-50e6-48fa-e053-2995a90ab21b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of Allopurinol Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f8b97d0-4d0b-9f4a-e063-6294a90a033f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c0f5af5-a453-4641-933f-ccb2625fca39 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5644814c-3f61-5338-e063-6294a90ad6c9 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:165f2ebb-a099-4d31-b21a-93b341c39429 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92253e70-0b0c-4a0c-9bd6-ccea91000819 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bf1be4e-72ba-407c-90b3-b70b09a25d6e (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2caa5246-9422-4826-b926-a2566506d3eb (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3db4e043-71ff-496a-8087-3fde0e352abf (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1bfae2-116f-4ef9-bb7b-3b69ac74df03 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of Allopurinol Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f27f578-f965-04c9-e063-6394a90a1ae2 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3198e1b-6344-ad96-e053-2995a90a4aaf (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ce5aab-76cf-465d-8f14-c745d382cd15 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30529a62-f95a-40e0-b4c5-2cfc09232068 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a80fe56f-8d03-423f-8e2a-7ec8c9e5045b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4deeebe3-fccc-2082-e063-6294a90a0c78 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00b27899-e68f-e9d9-e063-6394a90a88cb (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6c5b5c0-b1cb-44c0-a849-5d317e6fa300 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f130c9c0-45d8-42bc-a040-04bb077671f8 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73a374a6-ea1a-40a1-b6eb-d42654df0895 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20eef55e-0d70-874b-e063-6394a90aa06a (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:994b3117-b83e-44d9-910c-1c3a26ef838e (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e453a5e0-44c3-4eb5-a8d0-7c02157d2f8c (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8047206e-305b-44d2-aa61-dff0366e7675 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78978de2-1842-4570-9d11-67f13cc37ad5 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95a1ca8c-9855-4b11-92cd-6fdc144f0d3b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5efa81be-e2c9-4fb7-bd0d-aeca3920a393 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47b8c920-4648-604e-e063-6294a90a1f54 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a00a35a-cc85-0088-e063-6394a90a0744 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3b9dcf4-cada-4f79-befc-319c7dff15eb (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2462b4b5-8313-4e4d-93ac-839de4a29520 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20015399-43f8-4917-8ffe-dd8055c75712 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:005048dd-844f-468c-bf56-1a09727e3477 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d34fab-250c-496a-93f5-c8d9f52a2276 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36c1c908-1eed-ed2a-e063-6294a90a16f9 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9232f484-a5f6-4c63-b7f4-b510d2827159 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b926e62-3a9c-424a-833a-8169e55a1f15 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d83fec65-396a-40bd-8ee8-828d8930ea41 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df754efc-4b73-a0ab-e053-2a95a90a6133 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdc3f33b-ff2b-4a84-a820-51a497fdf3d9 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92d9a9d1-76c0-4435-984d-48f44b452855 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbfb3bde-2274-43cc-b726-d4578ebdb5d4 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b630c1cb-d4b7-4f80-b252-5947c1887def (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd8f8b8b-f25e-46e9-969a-65363b66e09b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc37bc7e-b6bc-4aa9-a6f3-6e11285c4f05 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:682dd8b8-fc6e-47c5-95b7-82d7ad96b750 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60750373-7146-455a-8d12-d0e32d2d4bc8 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f0134bf-b62f-1077-e063-6394a90a60b0 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb1b1aa6-cbd3-4b06-b9f9-9a0779a2da08 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d2f2f76-0f2b-45c4-affe-77bd927df589 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ae2d634-df53-40a8-a6bd-6fee7dacd754 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1da7d9d4-ed94-4fe6-827a-6f4b3bdce3c3 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:420d338d-4d0d-4e38-bfe2-a83256821b45 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b1c5cde-b2ed-ebc8-e063-6394a90a66c6 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48a9a6c3-4604-421e-a323-1133888aaf76 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dbced9a-ef6f-455e-8d5d-b635409521db (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42de3b18-a289-e49e-e063-6394a90a89d4 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f26674cd-d2b7-433c-a593-6a52012b81e3 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f5c4fbc-3d31-5068-e063-6294a90ab315 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:311ca755-c022-4251-97eb-dd9be86a993f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ce96b87-323d-40b6-a40b-32821e00d94c (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30ad5ba2-1cef-4933-b104-0597f6a2aaa2 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b943dbb1-7f54-434c-9439-8ce768d94ff4 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:156d743c-6324-44db-9230-21f762d64cfd (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2ab2389-ccaf-487b-9985-50e3539e7617 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90912dd4-5abf-4fd3-8fc1-3afd057b743f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0780dc78-d287-d5db-e063-6294a90aa1dd (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bcd1381-34d9-4fa5-bfc5-2566cb7a7638 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6341a72d-9c83-448c-871b-e800ad8f1547 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:583df4b8-a1d4-01ed-e063-6394a90af007 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36526c80-5a70-47c4-a0a6-785ccc346703 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:211e47c6-85b9-43e8-9e07-6cc4b8f708a0 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91c2183-e41d-45bc-87aa-edfca5eebac5 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f7642b-5046-47d6-b259-0c9f8aed3b34 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19a138b8-d225-03e6-f762-abe71560204b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of Allopurinol Tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5955ca3f-9383-4025-ac58-90394716493a (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c476ae27-fa13-480c-8d02-58c2c2904b84 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67d4aa7-6e5f-bba1-e053-2a95a90a1194 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3face45-f920-46a0-b707-6a66aa9735bd (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9961781-cfe8-459b-920d-eb000d45d41f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dca2d4f-0e93-4d1a-8d9f-b9b72867c242 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1c11f74-1de2-484c-b40b-d0013e8fd01a (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively.
1 to 2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c83ee9-c07b-9fc8-e053-6394a90a2160 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a22fa72-c363-4e96-e063-6394a90a48aa (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7003e410-b4ff-da07-5571-07e7e13f67e0 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:278df77c-3a9c-4c7d-ba8f-eb33f6335ef4 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1-2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99f4637-4d67-4b3c-8741-b775a9d0bde1 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b20c6ed4-6b94-4a1b-b448-e910856fa825 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:869e09f7-fb72-4e15-8d4b-849e86ebc6fd (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ca4baed-c5d8-4de4-ac17-6e5d1df15c03 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of the glomerular filtration rate, allopurinol has a plasma half-life of about 1-2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9a20bf5-15b9-4643-b829-40eacd4e849d (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dc4980c-8062-4239-a860-63888cabee46 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1-2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5c35283-09d2-4bb4-bdd1-055035fa272b (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faf55184-6962-d49f-e053-6394a90a152e (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae821c68-626a-474c-b81d-ce75d9795b3c (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d94f6643-621f-45ed-b2dc-26f84c5626ae (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b0e3f11-c02a-443d-806f-134c907ea371 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb8f09b6-c9f5-4deb-81e1-8d743e622126 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec09fbcf-6e20-8438-e053-2a95a90a6376 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0155151c-6e84-4f9b-9233-60ffa7483293 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aea483a7-4ce7-4fe5-936c-fd876b4fa3a8 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f5905f1-243e-4880-ad1c-d34064f17356 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06cf0f4b-aef0-472e-b5c0-56e0c35354f2 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44bcc8df-a803-010f-e054-00144ff88e88 (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3bd5852-8e43-6b5d-e053-2995a90a194f (opens source in a new tab)
Allopurinol label
Version not recorded · Effective date not recorded
Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=40Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.